Compositions and Methods for Identifying B Cell Malignancies Responsive to B Cell Depleting Therapy
Abstract:
The invention provides compositions and methods featuring the use of miR-629 for identifying subjects responsive to B-cell depleting therapies (e.g., treatment with an anti-CD19 antibody). In other embodiments, the invention features the use of miR-629 to identify subjects as having a B cell malignancy.
Information query
Patent Agency Ranking
0/0